CCL5 and inflammatory bowel disease: Mesalamine has been established as the first-line treatment for patients with mild-to-moderate ulcerative colitis, as it has been shown to reduce levels of Regulated upon Activation, Normal T cell Expressed and Secreted (RANTES), a proinflammatory chemokine elevated in patients with IBD and associated with platelet dysfunction.